Tiny Posted September 28, 2003 Share Posted September 28, 2003 Clinical Trial Information!!! http://info.med.yale.edu/dermatology/cl ... rials.html Clinical TrialsPhotopheresisTransimmunization a graduation from photopheresis to transimmunization developed by our scientists is proving successful fighting some cancers including CTCL. Transimmunization for the treatment of cutaneous T cell lymphoma (CTCL) Transimmunization was developed after years of laboratory research advanced the understanding of the underlying principles of ECP (Extracorporeal, photochemotherapy, or photopheresis). The scientific basis of ECP is the ability to stimulate the development of powerful stimulators of the immune system called dendritic cells. Transimmunization is a more efficient means by which to bring these dendritic cells in contact with target cancer cells, before they are returned to the body to stimulate an anti-tumor immune response. A clinical trial of Transimmunization for the treatment of cutaneous T cell lymphoma (CTCL) is currently underway at Yale. Patients must be 18 or more years of age; have a histologic confirmed diagnosis of CTCL; be at a clinical stage greater than 1B; have evidence of peripheral blood involvement by flow cytometry or molecular studies: and be able to tolerate intravenous fluid shifts. Treatments are given in an outpatient setting on 3 consecutive days (approximately 3 hours per day), repeated monthly for three months. Previous or current treatment with ECP does not make a patient ineligible for the study.For further information, please contact: Inger Christensen, RN Director of the Tissue Microarray Facility Department of Dermatology Yale University School of Medicine (203) 688-6445 email: firstname.lastname@example.org Additional links: http://www.transimmune.net http://www.transimmune.net/publications.html Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.